Clear Search

Showing 2 results for “Li T”.

November 2025

Low-dose belimumab reduced risk of flares in patients with systemic lupus erythematosus: A multicentre, randomised, double-blind, placebo-controlled trial

Ann Rheum Dis 2025 Doi: 10.1016/j.ard.2025.10.010. Epub ahead of print

Sun et al. provides the first RCT evidence that low-dose belimumab reduces flares in patients with SLE with low-grade disease activity. Authors evaluated the efficacy of low-dose belimumab for disease flare  prevention in Chinese patients with low-grade SLE (SELENA-SLEDAI ≤6).

more…

July 2023

Risk and Factors Associated with Disease Manifestations in Systemic Lupus Erythematosus - Lupus Nephritis (RIFLE-LN): A Ten-year Risk Prediction Strategy Derived from a Cohort of 1652 Patients

Front Immunol. 2023 14:1200732 DOI: 10.3389/fimmu.2023.1200732

Using data from a longitudinal cohort of SLE patients of Chinese origin, the authors identified risk factors for LN and developed a prediction model, RIFLE-LN, which demonstrated good performance in a testing cohort of 270 patients.

more…